

Additional Material

Contents

Additional Methods	2
Additional Table e1: Classification of the 38 cardiovascular diagnoses available on the CALIBER platform for use in cardio-oncology.	2
Additional Text e1: Methods used to predict CVD risks in four example Hodgkin lymphoma patients	3
Additional Results: Figures	5
Additional Figure e1: Incidence rates for all relevant CVDs, by age and sex, and including conduction defects and pericardial effusion (Method A1)	5
Additional Figure e2: Incidence rates for all relevant cardiovascular diseases, including and excluding events recorded as conduction defects and pericardial effusion, by age	6
Additional Figure e3: Incidence rate of all relevant CVDs, ignoring conduction defects and pericardial effusion, by age and sex (Method A2)	7
Additional Figure e4: Incidence rate of all relevant heart disease, ignoring conduction defects and pericardial effusion, by age and sex (Method B2)	8
Additional Results: Tables	9
Additional Table e2: Contributions of each of the five categories to incidence rates of all relevant CVDs (Method A1)	9
Additional Table e3: Contributions of each of the four categories to incidence rates of all relevant CVDs, ignoring conduction defects and pericardial effusion (Method A2)	11
Additional Table e4: Contributions of each of the four categories to incidence rates of all relevant heart diseases (Method B1)	13
Additional Table e5: Contributions of each of the three categories to incidence rates of all relevant heart diseases, ignoring CDPE (Method B2)	15
Additional Table e6: Incidence rates for each of the five cardiovascular disease categories, calculated separately (Method C)	17
Additional Table e7: Incidence rates of 38 individual cardiovascular diseases, by age and sex	19
References	37

Additional Methods

Additional Table e1: Classification of the 38 cardiovascular diagnoses available on the CALIBER platform for use in cardio-oncology.

Diagnoses were excluded from our main analyses if they were not known to be increased following any cancer treatment (e.g. abdominal aortic aneurysm) or because they are likely to be transient and without lasting consequences (e.g. transient ischemic attack).

Ischemic heart disease	
<i>Inclusions</i>	<i>Exclusions</i>
Myocardial infarction	Stable angina
Unstable angina	Coronary heart disease, NOS
Cardiomyopathy & heart failure	
<i>Inclusions</i>	
Dilated cardiomyopathy	
Heart failure	
Hypertrophic cardiomyopathy	
Cardiomyopathy, other	
Valvular heart disease	
<i>Inclusions</i>	
Multiple valve disorder	
Non-rheumatic aortic valve disorder	
Non-rheumatic mitral valve disorder	
Rheumatic valve disorder	
Conduction defects & pericardial effusion	
<i>Inclusions</i>	<i>Exclusions</i>
Atrioventricular block, second degree	Atrial fibrillation
Atrioventricular block, third degree	Atrioventricular block, first degree
Bifascicular block	Left bundle branch block
Pericardial effusion	Right bundle branch block
Supraventricular tachycardia	Sick sinus syndrome
Trifascicular block	
Ventricular tachycardia	
Stroke, not specified as hemorrhagic	
<i>Inclusions</i>	<i>Exclusions</i>
Ischemic stroke	Intracerebral hemorrhage
Stroke, NOS	Transient ischemic attack
Other cardiovascular diseases	
	<i>Exclusions</i>
	Abdominal aortic aneurysm
	Hypertension
	Peripheral arterial disease
	Primary pulmonary hypertension
	Pulmonary embolism
	Raynaud's disease
	Secondary pulmonary hypertension
	Subarachnoid hemorrhage
	Subdural hematoma
	Venous thromboembolism, excluding PE

Abbreviations - NOS: not otherwise specified, PE: pulmonary embolus

Additional Text e1: Methods used to predict CVD risks in example Hodgkin lymphoma patients

We present predicted risks for a total of ten hypothetical Hodgkin lymphoma patients – one male and one female patient diagnosed at each of ages 20, 30, 40, 50, and 60. We assume that each of the ten patients has received the same anthracycline-based chemotherapy and the same radiotherapy doses to the organs at risk, and that these were the anthracycline dose and mean radiotherapy doses used to treat an average PET-negative patient with mediastinal Hodgkin lymphoma, based on treatments delivered to the RAPID trial cohort [1,2]. These average radiotherapy doses to the cardiovascular organs at risk are shown in Table 2.

For each patient, cumulative risks for each year up to 30 years following treatment were calculated for incidence of the five relevant CVD categories, based on incidence rates calculated in this study using Method A1. We took account of competing risks due to non-CVD mortality and incidence of CVDs at prior ages, as follows:

Background mortality

It was assumed that, for each patient, their mortality rate in the absence of any treatment effects would be equal to the appropriate age-and-sex-specific mortality rate in the general population. UK mortality rates were extracted from the WHO mortality database for 2013 [3] in 5-year age groups for male and female patients. Rates of CVD mortality were subtracted from all-cause mortality [2]. The predicted 30-year background CVD incidence risk for each patient, taking into account competing risks of non-CVD mortality or prior incident CVD (“competing risks”), was then calculated as follows.

Calculation of predicted CVD incidence taking account of competing risks

Let the annual incidence rate for the specific disease of interest during the n^{th} year after treatment be denoted by r_n^{sp} , and the corresponding death rate for all non-CVD causes be denoted by r_n^{oth} . Then the probability — or risk — of incidence of the specific disease of interest during year n , given that the individual has survived up to the beginning of year n and not experienced a CVD, is:

$$p_n^{sp} = 1 - e^{-r_n^{sp}}.$$

Also, the probability that the individual experienced the specific disease of interest or died of a non-CVD cause, given survival up to the beginning of year n and no incident CVD, is:

$$p_n^{sp+oth} = 1 - e^{-(r_n^{sp} + r_n^{oth})},$$

and the probability that the individual survived without experiencing a CVD to the end of year n , given survival up to the beginning of year n , is:

$$q_n^{sp+oth} = 1 - p_n^{sp+oth}.$$

Hence, the cumulative probability that the individual survived up to the beginning of year n and experienced no CVD is:

$$Q_{n-1}^{sp+oth} = Q_{n-2}^{sp+oth} \times q_{n-1}^{sp+oth},$$

where $Q_0^{sp+oth} = 1$,

i.e. the individual is assumed to be alive at the start and CVD-naive,

and the probability that the individual survived up to the beginning of year n and experienced a CVD during year n :

$$p_cr_n^{sp} = p_n^{sp} \times Q_{n-1}^{sp+oth} .$$

The cumulative probability —or cumulative risk — that the individual has experienced incident CVD by the end of year n (n -year cumulative incidence) is therefore:


$$\sum_{i=1}^n p_cr_i^{sp}$$

Predicting incidence risks with treatments for Hodgkin Lymphoma

Predictions of the 30-year cumulative incidence risk for each of the five CVD categories, taking into account the likely effects of treatment, were then obtained in a similar fashion to that described above for the prediction of 30-year cumulative background mortality and incidence risks. The effects of treatment were based on relative rates of CVD incidence derived from prior publications (Table 1). These were multiplied by age- and sex-specific CVD rates to obtain rates expected after treatment. Steps to take account of competing risks were then taken, as described above.


Figure 6 in the main paper shows the predicted cumulative risks for four of the example Hodgkin lymphoma patients if they received no treatment (black lines), if they received anthracycline-based chemotherapy only (blue lines), and if they received both anthracycline-based chemotherapy and radiotherapy (orange lines). Table 3 gives 30-year predicted risks with and without treatment for all ten example patients. Full details of the methods used to calculate cumulative risks, competing risks, and predicted excess risks due to anthracycline-based chemotherapy and radiotherapy have previously been published [2].

Additional Results: Figures




Additional Figure e1. Incidence rates of all relevant CVDs, by age and sex, and including conduction defects and pericardial effusion (Method A1).

Incidence rate of all relevant CVDs: Males




Incidence rate of all relevant CVDs: Females




Additional Figure e2. Incidence rates for all relevant cardiovascular diseases, including and excluding events recorded as conduction defects and pericardial effusion, by age. Top panel displays rates for females. Bottom panel displays rates for males.

All relevant CVDs, ignoring conduction defects and pericardial effusion (Method A2)




Contributions of individual CVD categories to all relevant CVDs, ignoring conduction defects and pericardial effusion (Method A2)




Additional figure e3: Incidence rate of all relevant CVDs, ignoring conduction defects and pericardial effusion, by age and sex (Method A2).

Top row: incidence rate for all relevant CVDs combined, excluding conduction defects and pericardial effusion, and calculated using Method A2. Bottom row: the contributions of individual CVD categories to the incidence rate of all relevant CVDs combined. In all four panels only an individual's first recorded diagnosis of any relevant CVD is included (see Tables 1 and e3). For each age and sex group, the sum of the rates across the four categories in the bottom row is equal to the corresponding rate for all relevant CVDs in the top row.

All relevant heart diseases, ignoring conduction defects and pericardial effusion (Method B2)



Contributions of individual CVD categories to all relevant heart diseases, ignoring conduction defects and pericardial effusion (Method B2)



Additional figure e4: Incidence rate of all relevant heart diseases, ignoring conduction defects and pericardial effusion, by age and sex (Method B2). Top row: incidence rate for all relevant heart diseases combined, excluding conduction defects and pericardial effusion, and calculated using Method B2. Bottom row: the contributions of individual heart disease categories to the incidence rate of all relevant heart diseases combined. In all four panels only an individual's first recorded diagnosis of any relevant heart disease is included (see Tables 1 and e5). For each age and sex group, the sum of the rates across the three categories in the bottom row is equal to the corresponding rate for all relevant heart diseases in the top row.

Additional Results: Tables

Additional Table e2: Contributions of each of the five categories to incidence rates of all relevant CVDs (Method A1)

For each individual only the first recorded diagnosis of CVD or of heart disease is included (i.e. method A1 in Figure 2).

Age (yrs)	Ischemic heart disease	Cardiomyopathy & heart failure	Valvular heart disease	Conduction defects & pericardial effusion	Non-hemorrhagic stroke
Females	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI
1-9	-- -	-- -	82 58 - 116	59 39 - 88	-- -
10-19	-- -	30 19 - 48	79 59 - 105	182 151 - 220	25 15 - 41
20-29	31 19 - 51	65 46 - 92	145 115 - 183	314 268 - 368	66 47 - 93
30-39	115 91-146	112 89 - 143	196 164 - 235	353 308 - 403	185 153 - 222
40-49	481 436 - 531	223 193 - 257	335 298 - 377	488 442 - 538	425 383 - 472
50-54	967 873 - 1070	426 365 - 496	544 475 - 623	561 491 - 641	855 768 - 953
55-59	1357 1238 - 1488	766 678 - 866	860 767 - 966	804 713 - 906	1142 1033 - 1263
60-64	1923 1779 - 2078	1188 1076 - 1311	1244 1129 - 1370	927 829 - 1037	1717 1581 - 1864
65-69	2488 2314 - 2674	1931 1779 - 2096	2287 2121 - 2466	1134 1019 - 1262	2586 2409 - 2776
70-74	3847 3596 - 4115	3479 3241 - 3735	3595 3353 - 3855	1550 1394 - 1724	4504 4231 - 4793
75-79	5754 5411 - 6118	6641 6272 - 7031	5655 5315 - 6016	2138 1933 - 2365	7584 7189 - 8001
80-84	8074 7599 - 8579	11,471 10,902 - 12,069	8271 7790 - 8781	2551 2290 - 2842	11,972 11,391 - 12,583
85+	13,384 12,746 - 14,054	24,323 23,457 - 25,220	11,055 10,476 - 11,665	3816 3482 - 4181	20,914 20,112 - 21,747
No. cases	7197	8036	6317	3532	8956
Person yrs	4,892,483	4,892,483	4,892,483	4,892,483	4,892,483
Crude rate	1471 1437 - 1505	1643 1607 - 1679	1291 1260 - 1323	722 698 - 746	1830 1793 - 1869
Age-std	1454 1421 - 1488	1650 1614 - 1686	1292 1260 - 1323	712 688 - 735	1828 1790 - 1865
Males					
1-9	-- -	-- -	72 50 - 103	91 66 - 126	32 18 - 54
10-19	-- -	42 29 - 62	85 65 - 110	149 122 - 181	22 13 - 36
20-29	57 41 - 81	92 70 - 121	97 74 - 126	189 156 - 229	34 22 - 53
30-39	299 258 - 345	147 119 - 180	132 106 - 164	199 167 - 238	144 117 - 178
40-49	1374 1296 - 1457	419 377 - 466	269 236 - 307	302 267 - 342	516 470 - 568
50-54	2924 2758 - 3099	745 663 - 836	536 468 - 614	479 415 - 553	1089 989 - 1198
55-59	4178 3963 - 4406	1286 1169 - 1415	984 882 - 1097	693 608 - 789	1972 1826 - 2131
60-64	5028 4782 - 5285	1885 1737 - 2044	1535 1403 - 1680	1028 921 - 1148	2902 2717 - 3098
65-69	5619 5338 - 5915	2910 2709 - 3125	2810 2613 - 3021	1482 1341 - 1637	4237 3994 - 4495
70-74	7771 7372 - 8191	4785 4475 - 5117	4247 3955 - 4560	2029 1830 - 2249	6464 6102 - 6848
75-79	9611 9091 - 10,161	7986 7513 - 8488	6520 6094 - 6975	3424 3120 - 3759	9696 9174 - 10,248
80-84	12,513 11,765 - 13,308	14,366 13,563 - 15,215	8745 8124 - 9414	4632 4186 - 5125	13,983 13,191 - 14,821
85+	17,790 16,707 - 18,943	28,155 26,783 - 29,596	12,128 11,240 - 13,087	7559 6865 - 8324	21,390 20,199 - 22,651
No. cases	11,464	7156	5143	3315	8327
Person yrs	4,773,726	4,773,726	4,773,726	4,773,726	4,773,726
Crude	2401 2358 - 2446	1499 1465 - 1534	1077 1048 - 1107	694 671 - 718	1744 1707 - 1782
Age-std rate	2857 2805 - 2910	2127 2078 - 2177	1427 1388 - 1466	883 853 - 913	2309 2259 - 2358

Table continued on next page

Table e2 continued

Both					
1-9	-- -	16 9 - 28	77 60 - 98	75 59 - 97	27 18 - 42
10-19	-- -	36 27 - 49	82 68 - 99	165 144 - 189	23 16 - 33
20-29	45 34 - 60	79 64 - 99	119 100 - 142	247 219 - 280	49 37 - 64
30-39	207 183 - 235	130 111 - 151	164 142 - 188	275 247 - 307	164 143 - 189
40-49	928 883 - 976	321 295 - 349	302 277 - 330	395 366 - 426	471 439 - 505
50-54	1947 1851 - 2048	586 534 - 642	540 491 - 595	520 471 - 573	972 905 - 1044
55-59	2753 2629 - 2882	1023 949 - 1103	922 851 - 998	749 686 - 818	1553 1461 - 1651
60-64	3420 3279 - 3566	1524 1431 - 1622	1384 1296 - 1478	976 902 - 1056	2288 2174 - 2409
65-69	3955 3792 - 4124	2389 2264 - 2522	2532 2403 - 2668	1297 1205 - 1395	3360 3210 - 3516
70-74	5607 5379 - 5844	4065 3871 - 4268	3887 3698 - 4086	1765 1639 - 1900	5383 5160 - 5616
75-79	7382 7083 - 7692	7208 6914 - 7516	6020 5751 - 6301	2681 2504 - 2871	8475 8156 - 8808
80-84	9781 9368 - 10,213	12,584 12,114 - 13,072	8453 8070 - 8855	3351 3113 - 3608	12,745 12,272 - 13,237
85+	14,762 14,203 - 15,342	25,520 24,783 - 26,280	11,390 10,901 - 11,901	4986 4666 - 5328	21,063 20,394 - 21,754
No. cases	18,660	15,192	11,460	6847	17,282
Person yrs	9,666,209	9,666,209	9,666,209	9,666,209	9,666,209
Crude rate	1930 1903 - 1958	1572 1547 - 1597	1186 1164 - 1207	708 692 - 725	1788 1761 - 1815
Age-std rate	2091 2061 - 2121	1852 1823 - 1882	1347 1322 - 1372	767 749 - 785	2044 2013 - 2074

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

Additional Table e3: Contributions of each of the four categories to incidence rates of all relevant CVDs, ignoring conduction defects and pericardial effusion (Method A2)

Age (yrs)	Ischemic heart disease	Cardiomyopathy & heart failure	Valvular heart disease	Non-hemorrhagic stroke
Females	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI
1-9	-- -	-- -	82 58-115	-- -
10-19	-- -	31 20-49	81 61-107	25 15-41
20-29	31 19-51	68 48-96	148 118-187	66 47-93
30-39	115 91-146	117 92-147	201 168-240	185 153-222
40-49	481 436-531	229 198-264	343 306-386	425 383-472
50-54	966 873-1069	444 382-516	574 503-655	854 767-952
55-59	1355 1236-1486	784 695-885	899 803-1006	1141 1032-1261
60-64	1920 1776-2075	1219 1106-1344	1267 1152-1395	1714 1579-1861
65-69	2483 2309-2669	1983 1829-2151	2369 2200-2551	2581 2404-2771
70-74	3838 3587-4106	3600 3358-3860	3673 3428-3935	4493 4221-4782
75-79	5735 5394-6098	6825 6451-7220	5777 5435-6142	7560 7166-7975
80-84	8039 7567-8542	11,613 11,042-12,214	8466 7980-8981	11,921 11,342-12,529
85	13,316 12,682-13,983	24,746 23,875-25,649	11,388 10,803-12,006	20,807 20,010-21,637
No. cases	7197	8244	6510	8956
Person yrs	4,898,474	4,898,474	4,898,474	4,898,474
Crude rate	1469 1436-1503	1683 1647-1720	1329 1297-1362	1828 1791-1866
Age-std rate	1450 1416-1483	1686 1650-1723	1327 1294-1359	1821 1784-1859
Males				
1-9	-- -	-- -	73 51-104	32 18-54
10-19	-- -	44 30-63	85 66-111	22 13-36
20-29	57 41-81	94 72-123	100 76-129	34 22-53
30-39	299 258-345	160 131-195	135 109-168	144 117-178
40-49	1373 1295-1456	436 393-483	280 246-319	516 469-568
50-54	2921 2756-3097	783 700-877	550 481-630	1088 989-1197
55-59	4174 3958-4401	1332 1213-1463	1000 897-1114	1970 1824-2128
60-64	5020 4776-5276	1960 1810-2123	1576 1442-1722	2897 2713-3093
65-69	5605 5325-5900	3029 2825-3248	2885 2686-3099	4227 3985-4484
70-74	7749 7351-8168	4958 4642-5295	4379 4083-4697	6446 6084-6829
75-79	9565 9047-10,112	8255 7776-8765	6723 6291-7184	9649 9130-10,199
80-84	12,428 11,686-13,218	41942 14,126-15,805	9102 8470-9781	13,888 13,103-14,722
85	17,614 16,541-18,756	28,907 27,523-30,359	12,795 11,886-13,773	21,178 19,999-22,427
No. cases	11,464	7453	5336	8327
Person yrs	4,778,987	4,778,987	4,778,987	4,778,987
Crude rate	2399 2355-2443	1560 1525-1595	1117 1087-1147	1742 1705-1780
Age-std rate	2846 2794-2898	2201 2151-2251	1478 1439-1518	2297 2248-2346

Table continued on next page

Table e3 continued

Both				
1-9	-- -	16 9-28	77 60-99	27 18-42
10-19	-- -	38 28-50	83 69-101	23 16-33
20-29	45 34-60	82 66-101	122 103-145	49 37-64
30-39	207 183-234	138 119-161	168 147-193	164 143-189
40-49	927 882-975	332 306-361	312 286-340	471 439-505
50-54	1945 1849-2046	614 561-672	562 512-618	971 904-1043
55-59	2749 2626-2878	1055 980-1136	949 877-1026	1551 1459-1649
60-64	3414 3274-3561	1576 1482-1677	1416 1327-1511	2284 2170-2405
65-69	3946 3784-4114	2473 2346-2608	2611 2480-2749	3352 3203-3508
70-74	5592 5365-5829	4209 4013-4416	3990 3798-4191	5369 5146-5601
75-79	7353 7056-7662	7429 7131-7740	6177 5905-6461	8442 8124-8773
80-84	9730 9318-10,159	12,895 12,420-13,388	8711 8322-9118	12,679 12,208-13,167
85+	14,664 14,109-15,241	26,051 25,308-26,816	11,829 11,332-12,348	20,924 20,259-21,610
No. cases	18,660	15,697	11,846	17,282
Person yrs	9,677,461	9,677,461	9,677,461	9,677,461
Crude rate	1928 1901-1956	1622 1597-1648	1224 1202-1246	1786 1759-1813
Age-std rate	2084 2054-2114	1904 1875-1934	1388 1363-1413	2036 2005-2066

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

Additional Table e4: Contributions of each of the four categories to incidence rates of all relevant heart diseases (Method B1)

Age (yrs)	Ischemic heart disease	Cardiomyopathy & heart failure	Valvular heart disease	Conduction defects & pericardial effusion
Females	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI
1-9	-- -	-- -	82 58-116	59 39-88
10-19	-- -	30 19-48	79 59-105	182 151-220
20-29	31 19-51	65 46-92	147 117-186	314 268-368
30-39	116 92-147	112 89-143	199 167-238	354 310-405
40-49	482 437-532	229 198-264	340 302-382	491 445-541
50-54	971 877-1074	438 377-510	572 501-653	568 498-648
55-59	1359 1240-1489	790 701-891	877 782-983	811 720-913
60-64	1925 1781-2080	1242 1128-1368	1274 1158-1402	931 832-1041
65-69	2498 2325-2685	1969 1816-2136	2344 2176-2525	1132 1017-1260
70-74	3861 3611-4129	3577 3336-3835	3689 3444-3951	1608 1449-1784
75-79	5736 5395-6098	6881 6507-7276	5825 5482-6190	2189 1983-2417
80-84	7992 7523-8489	12,018 11,440-12,624	8467 7984-8978	2611 2349-2902
85+	13,241 12,614-13,899	25,682 24,803-26,592	11,460 10,878-12,073	3881 3549-4245
No. cases	7259	8513	6570	3607
Person yrs	4,905,948	4,905,948	4,905,948	4,905,948
Crude	1480 1446-1514	1735 1699-1772	1339 1307-1372	735 712-760
Age-std	1450 1417-1483	1721 1684-1757	1327 1295-1360	721 698-745
Males				
1-9	-- -	-- -	72 50-103	91 66-126
10-19	-- -	42 29-62	85 65-110	149 122-181
20-29	57 41-81	92 70-121	99 76-129	189 156-229
30-39	300 260-347	151 123-185	136 110-169	199 167-238
40-49	1375 1297-1457	432 389-479	281 247-319	305 269-345
50-54	2921 2755-3096	751 669-843	566 496-646	486 421-561
55-59	4172 3957-4399	1308 1190-1437	1008 905-1123	699 615-796
60-64	5031 4787-5287	1948 1798-2109	1584 1449-1730	1034 926-1153
65-69	5597 5317-5891	3019 2815-3237	2917 2717-3131	1515 1373-1672
70-74	7716 7321-8133	4976 4661-5312	4368 4074-4684	2089 1888-2311
75-79	9574 9059-10,118	8259 7782-8766	6724 6295-7183	3511 3205-3847
80-84	12,307 11,574-13,086	14,960 14,149-15,816	9086 8460-9759	4847 4395-5345
85+	17,466 16,407-18,593	29,521 28,136-30,976	12,633 11,738-13,597	7785 7089-8550
No. cases	11,519	7530	5390	3423
Person yrs	4,787,358	4,787,358	4,787,358	4,787,358
Crude	2406 2363-2450	1573 1538-1609	1126 1096-1156	715 691-739
Age-std	2839 2787-2890	2211 2161-2261	1477 1438-1517	904 873-934

Table continued on next page

Table e4 continued

Both				
1-9	-- -	17 10-29	77 60-98	75 59-97
10-19	-- -	36 27-49	82 68-99	165 144-189
20-29	45 34-60	79 64-99	121 102-144	247 219-280
30-39	208 184-236	132 113-154	167 146-192	276 248-307
40-49	929 884-977	330 304-359	310 284-338	398 369-430
50-54	1947 1851-2048	595 543-652	569 518-625	527 478-581
55-59	2751 2628-2880	1046 971-1127	942 871-1018	756 692-825
60-64	3424 3283-3570	1583 1488-1683	1423 1334-1519	980 907-1060
65-69	3952 3790-4120	2462 2335-2595	2613 2482-2750	1312 1220-1411
70-74	5593 5367-5830	4205 4009-4411	3994 3804-4195	1824 1696-1961
75-79	7360 7064-7668	7464 7166-7774	6206 5934-6489	2749 2570-2939
80-84	9656 9249-10,081	13,152 12,676-13,647	8706 8320-9109	3473 3233-3732
85+	14,565 14,017-15,134	26,885 26,137-27,654	11,827 11,335-12,341	5105 4785-5446
No. cases	18,778	16,043	11,960	7030
Person yrs	9,693,306	9,693,306	9,693,306	9,693,306
Crude	1937 1910-1965	1655 1630-1681	1234 1212-1256	725 708-742
Age-std	2082 2052-2111	1929 1899-1959	1389 1364-1414	781 763-800

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

Additional Table e5: Contributions of each of the three categories to incidence rates of all relevant heart diseases, ignoring CDPE (Method B2)

Age (yrs)	Ischemic heart disease	Cardiomyopathy & heart failure	Valvular heart disease
Females	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI
1-9	-- --	-- --	82 58-115
10-19	-- --	31 20-49	81 61-107
20-29	31 19-51	68 48-96	151 120-189
30-39	116 92-146	117 92-147	204 171-244
40-49	482 437-532	235 204-270	348 310-391
50-54	970 876-1073	456 394-529	604 531-687
55-59	1357 1238-1487	809 719-911	915 818-1023
60-64	1922 1778-2077	1274 1158-1401	1301 1184-1429
65-69	2493 2320-2679	2022 1866-2190	2426 2255-2610
70-74	3852 3602-4119	3697 3452-3959	3771 3524-4036
75-79	5717 5378-6077	7075 6696-7475	5953 5607-6321
80-84	7957 7491-8452	12,186 11,605-12,795	8664 8177-9180
85+	13,172 12,548-13,827	26,094 25,210-27,009	11,833 11,243-12,454
No. cases	7259	8729	6775
Person yrs	4,912,064	4,912,064	4,912,064
Crude	1478 1444-1512	1777 1740-1815	1379 1347-1412
Age-std	1445 1412-1479	1758 1721-1795	1364 1332-1397
Males			
1-9	-- --	-- --	73 51-104
10-19	-- --	44 30-63	85 66-111
20-29	57 41-81	94 72-123	101 78-131
30-39	300 260-347	164 135-199	139 113-172
40-49	1374 1296-1456	450 407-499	291 257-331
50-54	2918 2753-3094	790 706-883	580 509-661
55-59	4167 3952-4394	1353 1233-1485	1024 920-1139
60-64	5022 4779-5278	2023 1871-2188	1625 1489-1773
65-69	5583 5304-5876	3141 2934-3363	2993 2790-3209
70-74	7693 7299-8108	5146 4826-5488	4499 4200-4819
75-79	9527 9015-10,069	8533 8049-9046	6937 6502-7402
80-84	12,219 11,491-12,993	15,537 14,713-16,406	9457 8820-10,141
85+	17,282 16,234-18,397	30,265 28,869-31,729	13,282 12,368-14,264
No. cases	11,519	7837	5590
Person yrs	4,792,811	4,792,811	4,792,811
Crude	2403 2360-2448	1635 1599-1672	1166 1136-1197
Age-std	2827 2775-2879	2285 2234-2336	1529 1489-1569

Table continued on next page

Table e5 continued

Both			
1-9	-- --	17 10-29	77 60-99
10-19	-- --	38 28-50	83 69-101
20-29	45 34-60	82 66-101	124 105-148
30-39	208 184-236	140 121-163	172 150-197
40-49	928 883-976	343 316-372	320 293-348
50-54	1946 1850-2046	623 570-682	592 540-649
55-59	2748 2624-2877	1078 1002-1160	969 897-1046
60-64	3418 3278-3564	1636 1539-1738	1457 1367-1554
65-69	3943 3782-4111	2547 2418-2683	2692 2559-2831
70-74	5578 5352-5814	4348 4149-4557	4098 3905-4301
75-79	7330 7036-7637	7692 7390-8006	6370 6096-6657
80-84	9603 9199-10,026	13,480 12,999-13,979	8970 8580-9379
85	14,465 13,921-15,030	27,406 26,653-28,179	12,289 11,788-12,810
No. cases	18,778	16,566	12,364
Person yrs	9,704,874	9,704,874	9,704,874
Crude	1935 1907-1963	1707 1681-1733	1274 1252-1297
Age-std	2074 2045-2104	1982 1952-2012	1431 1406-1456

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

Additional Table e6: Incidence rates for each of the five cardiovascular disease categories, calculated separately (Method C)

Age (yrs)	Ischemic heart disease	Cardiomyopathy & heart failure	Valvular heart disease	Conduction defects & pericardial effusion	Non-hemorrhagic stroke
Females	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI	Rate* 95% CI
1-9	--	--	82 58-115	61 41-91	--
10-19	--	32 20-50	83 63-110	186 155-224	25 15-41
20-29	37 23-59	76 55-105	159 127-198	328 281-383	66 47-93
30-39	129 103-161	137 111-170	228 193-270	377 331-430	189 157-227
40-49	512 465-563	312 276-353	410 368-456	530 483-582	441 398-489
50-54	1030 934-1136	626 552-710	698 620-787	667 591-754	885 796-984
55-59	1463 1339-1598	1082 976-1199	1106 999-1224	928 830-1036	1180 1070-1302
60-64	2073 1924-2233	1702 1568-1848	1598 1468-1739	1096 989-1214	1793 1655-1943
65-69	2658 2480-2849	2696 2517-2889	2967 2778-3169	1411 1283-1552	2735 2554-2929
70-74	4319 4055-4600	5051 4765-5354	4711 4436-5004	2160 1976-2361	4730 4453-5024
75-79	6603 6241-6986	9350 8917-9804	7807 7412-8223	2882 2647-3138	7998 7598-8419
80-84	9425 8924-9954	15,993 15,333-16,680	11,690 11,129-12,279	3596 3293-3928	12,664 12,079-13,277
85+	15,552 14,889-16,245	33,197 32,213-24,211	17,283 16,581-18,015	5311 4932-5720	22,669 21,862-23,506
No. cases	8387	11,637	9000	4530	9854
Person yrs	4,935,493	4,933,281	4,933,277	4,940,722	4,933,254
Crude	1699 1663-1736	2359 2316-2402	1824 1787-1862	917 891-944	1997 1958-2037
Age-std	1637 1601-1672	2297 2255-2339	1777 1740-1814	888 862-914	1937 1898-1975
Males					
1-9	--	--	73 51-104	92 67-127	32 18-54
10-19	--	45 31-64	89 69-115	154 127-187	23 14-38
20-29	57 41-81	111 87-143	113 88-145	192 159-232	34 22-53
30-39	308 267-355	208 175-248	166 136-201	223 188-264	147 120-181
40-49	1409 1330-1492	649 597-707	407 366-453	413 372-459	540 492-593
50-54	3025 2857-3203	1301 1192-1419	809 725-904	686 608-773	1118 1018-1228
55-59	4341 4122-4572	2099 1948-2260	1414 1291-1547	992 890-1105	2056 1908-2216
60-64	5329 5078-5591	3044 2857-3244	2327 2164-2503	1485 1356-1626	3036 2849-3236
65-69	6020 5732-6323	4613 4362-4878	4006 3772-4253	2062 1896-2241	4431 4185-4691
70-74	8448 8038-8879	7315 6935-7716	6090 5744-6456	2981 2743-3240	6875 6507-7264
75-79	10,722 10,184-11,288	11,949 11,380-12,545	9547 9040-10,082	4823 4469-5206	10,356 9828-10,913
80-84	14,152 13,380-14,968	21,068 20,120-22,061	13,726 12,966-14,529	6550 6034-7109	14,854 14,062-15,691
85+	20,722 19,603-21,905	39,539 37,967-41,175	20,239 19,132-21,411	10,797 10,001-11,655	22,578 21,405-23,815
No. cases	12,719	11,259	7984	4776	9126
Person yrs	4,813,881	4,819,517	4,822,209	4,827,630	4,820,239
Crude	2642 2597-2688	2336 2293-2380	1656 1620-1692	989 962-1018	1893 1855-1933
Age-std	3114 3060-3168	3162 3104-3221	2154 2107-2202	1228 1193-1263	2437 2387-2487

Table continued on next page

Table e6 continued

Both					
1-9	--	17 10-29	77 60-99	77 60-99	27 18-42
10-19	--	38 29-51	86 72-104	170 148-194	24 17-34
20-29	48 36-63	95 78-116	134 114-158	255 226-288	49 37-64
30-39	219 194-247	173 151-198	197 173-223	300 270-332	168 146-193
40-49	961 914-1009	481 449-516	408 379-440	471 439-506	491 458-526
50-54	2029 1931-2132	964 898-1036	754 695-818	677 621-737	1002 934-1075
55-59	2888 2762-3020	1586 1494-1685	1259 1177-1347	960 888-1037	1615 1521-1714
60-64	3646 3501-3796	2352 2236-2473	1951 1846-2062	1285 1200-1375	2395 2278-2517
65-69	4238 4071-4411	3598 3445-3758	3457 3307-3613	1718 1613-1829	3534 3382-3692
70-74	6179 5942-6425	6073 5838-6316	5334 5114-5563	2531 2382-2690	5698 5471-5934
75-79	8352 8041-8676	10,456 10,106-10,817	8548 8233-8875	3708 3504-3925	9001 8677-9337
80-84	11,256 10,824-11,705	17,962 17,412-18,529	12,481 12,026-12,955	4743 4467-5036	13,514 13,038-14,006
85+	17,186 16,607-17,786	35,200 34,360-36,061	18,220 17,622-18,838	7044 6679-7429	22,640 21,972-23,329
No. cases	21,106	22,896	16,984	9306	18,980
Person yrs	9,749,375	9,752,798	9,755,487	9,768,351	9,753,493
Crude	2165 2136-2194	2348 2317-2378	1741 1715-1767	953 934-972	1946 1918-1974
Age-std	2306 2275-2337	2669 2634-2703	1935 1906-1964	1015 994-1035	2165 2134-2195

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

Additional Table e7: Incidence rates of 38 individual cardiovascular diseases, by age and sex

Age (yrs)	Stable angina		Myocardial infarction		Unstable angina		Coronary heart disease, not otherwise specified	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	-	-	--	-	--	-	--	-
10-19	22	13-37	--	-	--	-	--	-
20-29	45	30-69	27	15-46	--	-	27	15-46
30-39	144	117-178	100	78-129	80	61-106	62	45-86
40-49	695	641-754	374	335-418	307	272-347	206	178-239
50-54	1742	1616-1878	756	675-847	604	532-685	504	438-579
55-59	2191	2040-2354	1207	1096-1328	791	702-890	765	678-863
60-64	3228	3042-3425	1725	1592-1869	1135	1029-1253	1183	1074-1303
65-69	4212	3987-4449	2299	2137-2472	1495	1367-1636	1699	1561-1848
70-74	5912	5605-6235	4099	3853-4362	2263	2083-2459	2533	2342-2739
75-79	7546	7165-7946	6596	6255-6955	3194	2961-3445	3573	3328-3836
80-84	8267	7816-8745	9064	8613-9538	4645	4329-4983	4819	4500-5161
85	9106	8639-9598	15,081	14,506-15,679	6353	5990-6737	6557	6191-6945
No. cases	9893		8817		4813		5019	
Person yrs	5,013,521		5,112,049		5,129,844		5,143,172	
Crude	1973	1935-2013	1725	1689-1761	938	912-965	976	949-1003
Age-std	1846	1810-1882	1504	1472-1535	816	793-839	846	823-869
Males								
1-9	--	-	--	-	--	-	--	-
10-19	--	-	--	-	--	-	--	-
20-29	62	45-87	41	27-62	25	15-42	37	24-57
30-39	196	164-234	251	214-294	150	122-184	90	69-117
40-49	1214	1141-1291	1198	1126-1275	688	634-747	453	409-501
50-54	2807	2646-2977	2570	2417-2733	1424	1312-1546	922	833-1021
55-59	4633	4409-4868	3867	3664-4082	2075	1928-2232	1480	1358-1613
60-64	6059	5795-6335	4779	4548-5021	2569	2403-2746	2120	1971-2281
65-69	7278	6966-7604	5890	5615-6177	2861	2675-3060	2660	2482-2850
70-74	10,148	9708-10,608	8322	7938-8725	4088	3828-4366	3843	3594-4109
75-79	11,868	11,321-12,441	10,650	10,156-11,168	5320	4986-5677	4883	4568-5220
80-84	11,926	11,255-12,636	14,155	13,463-14,883	6682	6231-7166	6339	5908-6801
85	12,727	11,927-13,581	21,270	20,280-22,308	8493	7906-9124	8193	7627-8801
No. cases	13,518		13,411		7011		6121	
Person yrs	4,900,102		4,977,009		5,045,684		5,082,397	
Crude	2759	2713-2806	2695	2649-2741	1390	1357-1422	1204	1175-1235
Age-std	3066	3015-3118	2977	2927-3027	1462	1428-1496	1267	1235-1299

Table continued on next page

Table e7 continued

Both								
1-9	--	-	--	-	--	-	--	-
10-19	18	12-28	--	-	--	-	--	-
20-29	54	42-71	34	25-48	22	15-33	32	23-45
30-39	170	149-195	176	154-201	115	98-136	76	62-93
40-49	955	909-1003	786	745-830	498	465-533	330	303-358
50-54	2277	2174-2385	1665	1578-1758	1016	948-1089	714	658-776
55-59	3405	3269-3547	2528	2412-2650	1433	1346-1525	1124	1048-1205
60-64	4604	4443-4771	3209	3077-3347	1840	1741-1945	1646	1553-1745
65-69	5669	5478-5867	4006	3850-4169	2156	2043-2275	2167	2054-2286
70-74	7845	7582-8117	6035	5812-6266	3119	2963-3285	3153	2997-3318
75-79	9416	9093-9750	8361	8070-8662	4147	3948-4357	4167	3970-4375
80-84	9714	9330-10,113	11,092	10,702-11,495	5487	5221-5766	5456	5194-5731
85+	10,263	9852-10,691	17,065	16,559-17,587	7068	6754-7396	7113	6801-7438
No. cases	23,411		22,228		11,824		11,140	
Person yrs	9,913,623		10,089,058		10,175,528		10,225,569	
Crude	2361	2331-2392	2203	2174-2232	1162	1141-1183	1089	1069-1110
Age-std	2403	2372-2434	2173	2144-2201	1117	1097-1137	1042	1023-1061

Table continued on next page

Table e7 continued

Age (yrs)	Heart failure		Dilated cardiomyopathy		Hypertrophic cardiomyopathy		Cardiomyopathy, other	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	--	-	--	-	--	-	--	-
10-19	--	-	--	-	--	-	18	10-33
20-29	55	38-81	--	-	--	-	41	26-64
30-39	98	76-127	30	19-47	--	-	59	43-82
40-49	301	266-341	53	39-71	--	-	96	77-119
50-54	651	576-735	58	39-87	30	17-53	131	100-172
55-59	1122	1016-1239	103	74-143	43	26-71	215	171-270
60-64	1879	1741-2029	148	113-195	83	57-119	245	199-303
65-69	3088	2901-3288	183	142-237	87	60-126	352	292-423
70-74	6122	5820-6440	250	195-320	95	64-142	509	428-605
75-79	11,063	10,619-11,525	221	166-293	110	74-164	644	546-760
80-84	19,253	18,585-19,944	172	120-246	120	78-184	482	389-597
85+	37,791	36,848-38,758	125	83-188	146	100-214	597	496-720
No. cases	15,530		405		206		937	
Person yrs	5,105,261		5,173,311		5,174,524		5,170,448	
Crude	3042	2994-3090	78	71-86	40	35-46	181	170-193
Age-std	2641	2599-2682	72	65-79	36	31-40	164	154-175
Males								
1-9	--	-	--	-	--	-	--	-
10-19	23	14-38	--	-	--	-	32	21-49
20-29	68	49-93	20	11-35	--	-	48	33-70
30-39	163	134-198	47	33-68	29	18-47	68	51-93
40-49	633	582-690	153	128-182	61	46-80	185	158-217
50-54	1335	1227-1453	241	197-294	67	46-98	365	311-429
55-59	2377	2221-2545	315	262-380	79	55-115	460	395-537
60-64	3612	3415-3821	369	310-440	107	78-148	627	548-716
65-69	5779	5513-6059	492	419-577	81	55-120	836	740-945
70-74	9716	9309-10,140	558	469-664	114	78-167	938	820-1073
75-79	15,699	15,110-16,310	628	522-754	143	97-210	1314	1157-1492
80-84	26,582	25,645-27,553	585	466-735	158	102-244	1365	1176-1585
85+	47,233	45,749-48,765	526	399-694	--	-	1532	1302-1803
No. cases	16,484		1029		281		1797	
Person yrs	5,035,167		5,113,356		5,118,089		5,108,442	
Crude	3274	3224-3324	201	189-214	55	49-62	352	336-368
Age-std	3865	3806-3924	199	187-212	53	47-60	356	340-373

Table continued on next page

Table e7 continued

Both								
1-9	15	8-26	--	-	--	-	--	-
10-19	20	13-30	--	-	11	7-19	26	18-36
20-29	62	49-79	16	10-26	10	6-19	45	34-60
30-39	131	112-153	38	29-51	21	14-31	64	51-80
40-49	468	436-501	103	89-119	36	28-47	141	124-160
50-54	995	928-1067	150	126-180	49	36-67	249	217-286
55-59	1751	1655-1852	210	178-246	61	45-83	338	298-384
60-64	2733	2612-2860	258	223-298	95	75-121	434	388-486
65-69	4391	4229-4560	334	292-382	84	64-110	588	531-651
70-74	7808	7557-8067	396	344-457	104	79-137	713	641-792
75-79	13,137	12,775-13,509	406	348-473	125	95-165	949	858-1049
80-84	22,268	21,715-22,836	345	285-419	136	100-185	853	754-964
85+	40,944	40,141-41,763	261	208-329	118	84-166	915	809-1034
No. cases	32,014		1434		487		2734	
Person yrs	10,140,428		10,286,667		10,292,613		10,278,889	
Crude	3157	3123-3192	139	132-147	47	43-52	266	256-276
Age-std	3180	3145-3214	132	125-139	45	41-49	253	243-262

Table continued on next page

Table e7 continued

Age (yrs)	Multiple valve disorder		Non-rheumatic aortic valve disorder		Non-rheumatic mitral valve disorder		Rheumatic valve disorder	
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Females								
1-9	--	-	--	-	48	31-76	--	-
10-19	--	-	25	15-41	56	40-79	--	-
20-29	33	20-54	31	19-51	94	71-126	33	20-54
30-39	34	22-53	69	51-93	127	101-158	54	38-76
40-49	108	88-133	141	118-169	244	213-280	52	38-69
50-54	184	147-232	281	233-338	391	334-457	96	70-132
55-59	373	314-443	434	370-509	533	461-615	149	114-196
60-64	522	452-604	747	662-844	763	677-861	194	153-246
65-69	1006	902-1122	1458	1332-1597	1352	1231-1486	318	262-386
70-74	1920	1756-2099	2565	2374-2772	2084	1912-2272	657	564-766
75-79	3539	3297-3799	4240	3972-4526	3311	3075-3564	1076	946-1223
80-84	5354	5019-5712	6341	5973-6733	4000	3710-4313	1458	1289-1649
85+	8478	8064-8913	9583	9136-10,051	4997	4680-5335	1800	1616-2005
No. cases	4542		5487		4210		1348	
Person yrs	5,162,074		5,144,956		5,140,995		5,168,112	
Crude	880	855-906	1066	1039-1095	819	795-844	261	247-275
Age-std	733	711-754	907	883-931	718	696-739	225	213-237
Males								
1-9	--	-	53	35-81	29	17-51	--	-
10-19	21	13-36	46	32-66	34	22-51	--	-
20-29	43	29-64	43	29-64	37	24-57	--	-
30-39	33	21-50	67	49-91	98	76-126	37	25-56
40-49	138	115-166	140	117-167	202	174-235	52	39-70
50-54	261	215-315	390	334-456	395	338-462	97	71-132
55-59	474	407-551	646	567-735	677	596-769	170	132-219
60-64	788	700-888	1172	1062-1292	1084	979-1200	229	184-286
65-69	1369	1244-1507	2331	2166-2509	1713	1572-1866	397	332-474
70-74	2420	2226-2632	3696	3453-3957	2347	2156-2556	531	444-634
75-79	4056	3772-4361	5592	5254-5953	3711	3439-4005	968	835-1122
80-84	6435	6004-6896	8156	7663-8681	4802	4430-5205	1410	1218-1634
85+	9672	9060-10,325	12,300	11,597-13,046	5732	5263-6242	1999	1734-2306
No. cases	4121		5638		3880		1055	
Person yrs	5,107,705		5,086,375		5,093,399		5,115,694	
Crude	807	783-832	1108	1080-1138	762	738-786	206	194-219
Age-std	890	863-917	1232	1200-1264	813	787-838	221	208-235

Table continued on next page

Table e7 continued

Both									
1-9	--	-	40	28-56	39	27-55	17	10-29	
10-19	15	10-24	36	27-48	45	34-58	12	7-20	
20-29	38	28-52	37	27-51	64	50-81	25	17-36	
30-39	33	25-45	68	55-84	112	95-133	46	35-59	
40-49	123	107-141	141	124-160	223	201-247	52	42-64	
50-54	223	192-258	336	298-379	393	352-439	96	77-120	
55-59	423	378-475	540	488-597	605	550-666	160	133-192	
60-64	654	597-717	957	887-1033	922	853-997	212	180-249	
65-69	1184	1102-1272	1884	1779-1995	1529	1435-1629	356	312-406	
70-74	2158	2030-2293	3101	2946-3264	2209	2079-2347	597	532-671	
75-79	3774	3587-3971	4853	4639-5077	3493	3313-3683	1027	932-1131	
80-84	5808	5540-6089	7100	6800-7413	4337	4105-4582	1438	1308-1580	
85+	8883	8537-9243	10,502	10,120-10,899	5246	4980-5526	1868	1714-2036	
No. cases	8663		11,125		8090		2403		
Person yrs	10,269,779		10,231,331		10,234,394		10,283,807		
Crude	844	826-861	1087	1067-1108	790	773-808	234	225-243	
Age-std	803	786-819	1050	1031-1070	759	742-776	223	214-231	

Table continued on next page

Table e7 continued

Age (yrs)	Atrioventricular block, 2 nd degree		Atrioventricular block, 3 rd degree		Bifascicular block		Pericardial effusion		Supraventricular tachycardia		Trifascicular block		Ventricular tachycardia	
Females	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
1-9	--	-	--	-	--	-	--	-	36	21-60	--	-	--	-
10-19	--	-	--	-	--	-	23	14-39	140	113-173	--	-	20	11-35
20-29	--	-	--	-	--	-	25	14-43	282	238-333	--	-	27	15-46
30-39	20	11-35	--	-	--	-	54	38-76	286	247-332	--	-	44	30-65
40-49	26	17-40	23	15-36	--	-	93	75-117	396	356-441	--	-	52	38-69
50-54	35	21-60	35	21-60	--	-	172	135-218	427	367-497	--	-	91	66-126
55-59	54	35-85	57	37-89	--	-	241	194-298	609	532-697	--	-	120	89-163
60-64	88	62-126	103	74-142	--	-	265	216-325	642	563-732	--	-	145	111-191
65-69	124	91-169	196	153-251	--	-	463	395-544	789	697-892	--	-	171	131-223
70-74	246	192-316	409	337-496	--	-	600	511-704	1095	972-1233	--	-	302	241-378
75-79	400	324-494	575	483-686	78	48-125	800	690-928	1430	1278-1600	64	38-108	446	366-545
80-84	643	534-773	885	756-1036	132	87-198	843	717-991	1595	1417-1796	109	69-170	482	389-597
85+	969	836-1122	1743	1562-1946	380	300-480	886	760-1032	1600	1426-1796	396	315-498	571	471-691
No. cases	589		872		135		1175		2731		129		641	
Person yrs	5,173,166		5,171,581		5,175,911		5,171,892		5,138,482		5,175,832		5,171,827	
Crude	114	105-123	169	158-180	26	22-31	227	215-241	531	512-552	25	21-30	124	115-134
Age-std	96	88-104	140	130-149	21	17-24	203	191-214	490	472-509	19	16-23	110	102-119
Males														
1-9	--	-	--	-	--	-	--	-	70	49-101	--	-	--	-
10-19	--	-	--	-	--	-	--	-	126	101-156	--	-	17	9-30
20-29	--	-	--	-	--	-	32	20-51	157	128-194	--	-	--	-
30-39	--	-	21	21-36	--	-	54	38-76	153	125-188	--	-	46	31-66
40-49	31	21-46	26	17-40	--	-	105	85-129	234	204-270	--	-	104	84-128
50-54	92	66-127	79	56-112	--	-	169	133-214	378	323-444	--	-	154	120-197
55-59	105	76-145	108	78-148	--	-	227	182-282	561	488-645	--	-	284	233-345
60-64	183	143-234	250	202-308	44	26-72	314	260-379	710	626-806	46	28-76	503	433-584
65-69	325	267-395	371	308-445	97	68-139	475	404-558	905	804-1018	81	55-120	541	464-630
70-74	583	492-691	685	585-801	210	158-279	592	500-701	1178	1045-1328	210	158-279	844	733-973
75-79	1068	927-1229	1474	1307-1661	329	256-424	841	718-985	1533	1362-1725	472	382-583	1120	976-1286
80-84	1341	1153-1559	2008	1774-2271	560	444-707	964	807-1151	1557	1353-1793	790	649-961	1430	1236-1655
85+	2231	1948-2554	3768	3394-4183	1265	1058-1513	1107	914-1340	2028	1758-2338	2052	1783-2362	1526	1296-1797
No. cases	988		1344		359		1075		2281		479		1357	
Person yrs	5,116,015		5,113,725		5,119,770		5,116,182		5,094,729		5,119,186		5,112,235	
Crude	193	181-206	263	249-277	70	63-78	210	198-223	448	430-466	94	86-102	265	252-280
Age-std	212	198-225	295	279-310	80	72-88	216	203-229	459	440-478	109	100-119	275	260-290

Table continued on next page

Table e7 continued

Both														
1-9	--	-	--	-	--	-	22	14-36	53	40-72	--	-	--	-
10-19	--	-	--	-	--	-	19	13-29	132	114-154	--	-	18	12-28
20-29	13	8-23	--	-	--	-	29	20-41	215	189-245	--	-	22	15-33
30-39	17	11-26	16	11-25	--	-	54	42-69	220	195-248	--	-	45	34-59
40-49	29	22-38	24	18-33	--	-	99	85-116	315	289-343	--	-	78	65-92
50-54	64	48-84	58	43-77	--	-	170	144-201	402	361-449	--	-	123	101-150
55-59	80	61-104	83	64-107	16	9-28	234	201-272	585	531-644	--	-	202	172-239
60-64	135	110-165	176	147-210	26	16-41	289	252-332	676	617-740	29	19-45	323	283-368
65-69	222	188-262	281	243-326	57	41-79	469	418-526	845	776-921	51	36-72	352	308-401
70-74	406	353-468	540	478-610	116	90-151	596	531-669	1134	1042-1234	121	93-156	559	496-630
75-79	704	626-791	984	891-1086	192	154-241	819	735-913	1477	1361-1602	250	205-304	753	672-843
80-84	936	832-1052	1355	1230-1494	312	255-382	894	793-1008	1579	1442-1729	395	330-473	879	779-992
85+	1396	1264-1542	2428	2251-2619	680	590-784	961	852-1083	1746	1596-1910	957	849-1079	895	790-1013
No. cases	1577		2216		494		2250		5012		608		1998	
Person yrs	10,289,181		10,285,306		10,295,681		10,288,074		10,233,210		10,295,018		10,284,062	
Crude	153	146-161	215	207-225	48	44-52	219	210-228	490	476-504	59	55-64	194	186-203
Age-std	145	138-153	205	196-213	45	41-49	208	200-217	472	459-485	55	51-60	185	176-193

Table continued on next page

Table e7 continued

Age (years)	Ischemic stroke		Stroke, not otherwise specified	
Females	Rate*	95% CI	Rate*	95% CI
1-9	--	-	--	-
10-19	--	-	--	-
20-29	43	28-66	29	17-48
30-39	100	78-129	89	68-116
40-49	252	220-288	217	188-251
50-54	468	405-541	451	389-522
55-59	687	605-780	599	522-686
60-64	955	858-1063	934	838-1041
65-69	1605	1472-1750	1311	1191-1443
70-74	3029	2820-3253	2138	1963-2328
75-79	5114	4819-5427	3577	3331-3841
80-84	8074	7656-8515	5206	4871-5563
85+	14,835	14,276-15,417	8634	8206-9085
No. cases		7370		5031
Person yrs		5,140,505		5,133,139
Crude	1434	1401-1467	980	953-1008
Age-std	1209	1181-1236	843	819-866
Males				
1-9	--	-	--	-
10-19	18	10-32	--	-
20-29	21	12-38	--	-
30-39	109	86-139	46	31-66
40-49	344	306-386	227	197-261
50-54	694	617-781	487	424-561
55-59	1361	1244-1488	869	777-972
60-64	1945	1802-2098	1316	1200-1444
65-69	2917	2731-3116	1832	1685-1991
70-74	4545	4273-4834	2937	2720-3171
75-79	6780	6405-7176	4038	3751-4347
80-84	9521	8986-10,088	5456	5054-5890
85+	14,164	13,405-14,966	8216	7640-8836
No. cases		7299		4487
Person yrs		5,079,405		5,079,287
Crude	1437	1404-1470	883	858-910
Age-std	1573	1537-1610	963	935-991

Table continued on next page

Table e7 continued

Both				
1-9	--	-	17	10-29
10-19	18	12-27	--	-
20-29	31	22-44	21	14-32
30-39	105	88-124	67	54-83
40-49	298	273-325	222	200-246
50-54	582	532-638	469	424-519
55-59	1025	953-1103	735	674-801
60-64	1444	1357-1537	1123	1047-1205
65-69	2244	2129-2365	1565	1469-1666
70-74	3745	3575-3925	2516	2376-2663
75-79	5867	5631-6113	3786	3597-3985
80-84	8678	8344-9024	5310	5051-5584
85+	14,608	14,155-15,076	8492	8146-8854
No. cases	14,669		9518	
Person yrs	10,219,909		10,212,426	
Crude	1435	1412-1459	932	913-951
Age-std	1384	1362-1407	902	883-920

Table continued on next page

Table e7 continued

Age (yrs)	Atrial fibrillation		Atrioventricular block, 1 st degree		Left bundle branch block		Right bundle branch block		Sick sinus syndrome	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	--	-	--	-	--	-	--	-	--	-
10-19	22	13-37	--	-	--	-	50	35-71	--	-
20-29	66	46-93	--	-	--	-	86	64-117	--	-
30-39	138	111-171	25	15-41	36	24-55	77	58-103	--	-
40-49	409	368-455	38	27-54	96	77-119	122	101-148	13	7-24
50-54	842	756-938	61	41-90	192	153-240	200	160-249	33	19-57
55-59	1751	1617-1896	86	60-123	347	290-415	264	215-342	40	24-68
60-64	3066	2887-3256	168	130-217	534	463-617	340	284-407	68	46-102
65-69	5472	5218-5738	311	255-378	748	659-849	560	484-648	140	104-187
70-74	10,402	10,000-10,820	632	541-738	1477	1334-1635	855	748-978	322	259-400
75-79	18,384	17,794-18,993	1068	939-1215	2331	2136-2544	1573	1415-1749	594	500-706
80-84	28,473	27,629-29,342	2073	1869-2298	3866	3583-4171	2596	2367-2847	817	693-963
85+	47,991	46,880-49-128	4308	4017-4620	7054	6677-7452	5248	4926-5591	1063	924-1223
No. cases	21,509		1809		3548		2658		675	
Person yrs	5,051,596		5,170,099		5,162,356		5,166,741		5,171,954	
Crude	4258	4201-4315	350	334-366	687	665-710	514	495-534	131	121-141
Age-std	3911	3859-3963	283	270-296	569	550-588	429	412-445	110	102-118
Males										
1-9	--	-	--	-	--	-	--	-	--	-
10-19	37	25-55	--	-	--	-	72	54-96	--	-
20-29	168	137-205	--	-	20	11-35	100	77-130	--	-
30-39	331	289-380	24	15-41	36	24-54	127	102-159	--	-
40-49	816	757-879	67	51-87	153	128-182	211	182-245	15	9-27
50-54	1990	1856-2133	117	88-155	325	274-386	392	336-459	42	26-68
55-59	3409	3220-3610	249	202-307	443	378-518	577	502-662	59	39-91
60-64	5935	5679-6203	474	406-552	722	637-817	891	796-997	122	90-165
65-69	10,511	10,144-10,892	817	722-924	1246	1127-1378	1466	1337-1608	211	166-269
70-74	17,111	16,555-17,686	1606	1449-1779	2340	2149-2547	2455	2259-2667	351	282-437
75-79	25,627	24,841-26,438	2974	2733-3236	3894	3616-4194	4158	3870-4467	765	648-903
80-84	39,335	38,129-40,580	5082	4701-5493	5793	5385-6232	6217	5794-6672	1022	860-1215
85+	59,245	57-472-61,073	8788	8204-9413	10,355	9719-11,032	11,182	10,520-11,886	1241	1035-1487
No. cases	23,566		2984		3991		4589		636	
Person yrs	4,965,632		5,110,026		5,105,869		5,102,613		5,116,543	
Crude	4746	4686-4807	584	563-605	782	758-806	899	874-926	124	115-134
Age-std	5824	5749-5898	660	636-683	869	842-896	992	963-1020	135	125-146

Table continued on next page

Table e7 continued

Both					
1-9	-- -	-- -	-- -	16 9-28	-- -
10-19	29 21-41	-- -	-- -	61 49-77	-- -
20-29	120 101-143	18 12-28	12 7-21	94 77-114	13 8-23
30-39	235 209-264	25 17-35	36 27-48	102 86-122	11 6-18
40-49	613 576-651	53 43-65	124 109-142	167 148-188	14 10-21
50-54	1419 1339-1505	89 70-112	259 226-297	297 261-337	38 26-54
55-59	2579 2462-2702	168 140-201	395 351-444	421 375-472	50 36-69
60-64	4472 4316-4634	319 280-364	627 571-689	613 557-674	95 75-121
65-69	7893 7672-8121	558 503-620	991 916-1072	1002 927-1084	175 145-511
70-74	13,514 13,176-13,861	1094 1004-1192	1886 1767-2014	1613 1504-1732	335 287-392
75-79	21,572 21,091-22,063	1934 1802-2075	3041 2874-3218	2745 2586-2913	672 595-757
80-84	32,847 32-144-33,566	3331 3130-3544	4673 4434-4926	4108 3885-4345	903 802-1017
85+	51,646 50,697-52,613	5815 5537-6107	8171 7839-8518	7242 6931-7568	1123 1005-1255
No. cases	45,075	4793	7539	7247	1311
Person yrs	10,017,228	10,280,126	10,268,225	10,269,354	10,288,497
Crude	4500 4458-4541	466 453-480	734 718-751	706 690-722	127 121-135
Age-std	4756 4712-4800	442 429-454	698 682-714	671 656-687	121 115-128

Table continued on next page

Table e7 continued

Age (yrs)	TIA		Intracerebral hemorrhage		Subarachnoid hemorrhage		Subdural hematoma	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	--	-	--	-	--	-	--	-
10-19	--	-	--	-	--	-	--	-
20-29	41	26-64	--	-	33	20-54	--	-
30-39	135	108-167	33	21-51	62	45-86	--	-
40-49	354	316-397	69	54-90	119	97-145	22	14-34
50-54	748	668-839	144	111-187	215	174-266	28	15-50
55-59	1088	984-1204	204	161-257	187	146-238	52	32-82
60-64	1648	1519-1789	237	191-294	226	181-282	88	62-126
65-69	2087	1933-2252	401	338-477	246	197-307	93	65-133
70-74	3773	3537-4025	740	641-855	343	277-423	206	157-271
75-79	5751	5433-6088	1046	919-1192	401	325-495	349	279-437
80-84	7642	7227-8080	1686	1504-1891	580	477-705	619	512-747
85+	9972	9502-10,466	2677	2450-2925	619	516-744	951	820-1102
No. cases	7293		1634		858		536	
Person yrs	5,104,151		5,168,503		5,167,153		5,174,219	
Crude	1429	1396-1462	316	301-332	166	155-178	104	95-113
Age-std	1270	1241-1300	266	253-279	148	138-158	86	79-93
Males								
1-9	--	-	--	-	--	-	--	-
10-19	--	-	--	-	20	12-34	--	-
20-29	25	15-42	21	12-38	34	22-53	--	-
30-39	99	77-128	37	25-56	67	49-91	--	-
40-49	395	355-440	110	89-135	118	97-144	29	19-43
50-54	882	795-979	204	164-253	139	107-181	45	28-71
55-59	1601	1473-1739	287	236-348	176	137-226	74	50-108
60-64	2343	2186-2512	410	348-484	175	136-225	110	80-152
65-69	3366	3164-3580	694	607-793	273	221-339	237	188-298
70-74	5039	4749-5347	840	729-968	233	178-304	394	321-485
75-79	7000	6612-7410	1474	1307-1662	181	129-255	659	551-789
80-84	8989	8456-9555	2155	1913-2427	387	293-512	1417	1224-1640
85+	10,588	9911-11,310	2886	2562-3250	516	390-683	2317	2030-2646
No. cases	7319		1679		621		805	
Person yrs	5,046,705		5,111,299		5,113,502		5,117,208	
Crude	1450	1417-1484	328	313-345	121	112-131	157	147-169
Age-std	1588	1552-1624	348	332-365	121	111-130	175	163-187

Table continued on next page

Table e7 continued

Both				
1-9	-- -	-- -	-- -	-- -
10-19	14 9-23	14 9-23	16 10-25	-- -
20-29	32 23-45	18 12-28	33 24-47	12 7-21
30-39	117 99-138	35 26-47	65 52-80	13 8-21
40-49	375 347-405	90 76-105	118 103-136	25 19-34
50-54	816 755-881	174 147-206	177 150-208	36 25-52
55-59	1345 1262-1434	245 211-285	181 152-216	63 47-84
60-64	1992 1889-2100	323 283-368	200 170-237	99 78-126
65-69	2709 2582-2842	544 489-605	259 223-303	164 135-198
70-74	4370 4183-4565	788 712-871	290 246-343	296 251-349
75-79	6313 6064-6573	1241 1136-1355	301 251-360	490 426-564
80-84	8200 7869-8545	1883 1734-2045	499 425-585	954 850-1071
85+	10,179 9790-10,583	2748 2560-2950	584 501-681	1414 1281-1561
No. cases	14,612	3313	1479	1341
Person yrs	10,150,856	10,279,802	10,280,655	10,291,428
Crude	1439 1416-1463	322 311-333	144 137-151	130 124-137
Age-std	1418 1395-1441	304 294-315	136 129-143	123 116-129

Table continued on next page

Table e7 continued

Age (yrs)	Hypertension		Primary pulmonary hypertension		Secondary pulmonary hypertension		Raynauds	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	104	77-142	--	-	--	-	66	45-97
10-19	161	132-197	--	-	--	-	1112	1030-1199
20-29	951	868-1042	--	-	25	14-43	1045	957-1140
30-39	2927	2793-3068	20	11-35	21	12-37	1279	1191-1372
40-49	8543	8339-8752	59	44-78	53	39-71	1145	1074-1221
50-54	14,299	13,901-14,709	93	68-129	104	76-141	921	830-1021
55-59	18,074	17,574-18,589	126	94-169	135	101-179	941	844-1049
60-64	23,227	22,626-23,845	200	158-252	197	155-249	1053	950-1167
65-69	31,497	30,710-32,304	398	335-473	236	188-295	1142	1030-1266
70-74	43,947	42,778-45,147	704	608-816	575	489-677	1212	1083-1357
75-79	55,416	53,826-57,053	1064	936-1211	877	761-1011	1278	1135-1439
80-84	65,352	63,211-67,566	1680	1498-1884	1294	1136-1474	1219	1065-1396
85+	70,919	68,606-73,310	2237	2030-2464	1600	1428-1794	755	639-893
No. cases	46,949		1464		1163		5234	
Person yrs	4,185,552		5,169,913		5,174,950		5,107,807	
Crude	11,217	11,116-11,319	283	269-298	225	212-238	1025	997-1053
Age-std	14,856	14,722-14,991	239	226-251	191	180-202	1000	973-1027
Males								
1-9	124	94-163	--	-	--	-	39	24-63
10-19	171	142-205	--	-	--	-	377	332-427
20-29	739	671-813	--	-	--	-	285	244-332
30-39	3160	3021-3305	21	12-36	18	10-32	345	301-395
40-49	10,693	10,464-10,927	48	35-65	41	29-57	462	418-511
50-54	19,228	18,761-19,706	60	40-89	57	38-86	569	499-647
55-59	25,988	25,347-26,617	179	139-229	91	64-128	699	617-793
60-64	34,177	33,412-34,961	209	166-263	165	128-214	893	799-1000
65-69	42,502	41,524-43,502	422	356-502	269	217-334	791	697-898
70-74	49,796	48,463-51,166	763	658-885	521	435-623	939	821-1074
75-79	58,435	56,670-60,256	1073	932-1234	845	721-989	939	808-1092
80-84	65,991	63,610-68,461	1639	1431-1879	1515	1315-1745	1079	912-1278
85+	75,028	72,043-78,135	2105	1832-2419	2021	1754-2328	852	685-1061
No. cases	52,790		1132		911		2632	
Person yrs	4,210,136		5,115,818		5,119,777		5,090,552	
Crude	12,539	12,432-12,646	221	209-235	178	167-190	517	498-537
Age-std	17,820	17,668-17,972	239	225-253	194	182-207	506	487-525

Table continued on next page

Table e7 continued

Both					
1-9	114 93-140	-- -	-- -	52 39-71	
10-19	166 145-190	-- -	-- -	729 683-778	
20-29	837 783-895	14 9-24	16 10-26	637 590-687	
30-39	3044 2947-3145	20 14-30	20 13-29	808 759-860	
40-49	9614 9460-9770	53 43-65	47 37-58	801 759-845	
50-54	16,745 16,438-17,059	76 59-98	80 63-102	742 685-805	
55-59	21,949 21,553-22,352	152 126-184	112 90-140	819 754-889	
60-64	28,451 27,967-28,943	204 173-241	181 152-216	974 902-1050	
65-69	36,637 36,015-37,270	410 363-463	252 216-295	970 895-1050	
70-74	46,670 45,786-47,571	732 659-813	549 487-620	1082 992-1180	
75-79	56,807 55,620-58,019	1068 971-1175	862 776-958	1123 1023-1233	
80-84	65,639 64,039-67,279	1663 1523-1815	1387 1260-1526	1160 1044-1290	
85+	72,509 70,670-74,395	2192 2025-2373	1743 1595-1905	788 690-900	
No. cases	99,739	2596	2074	7866	
Person yrs	8,395,688	10,285,731	10,294,728	10,198,358	
Crude	11,880 11,806-11,954	252 243-262	201 193-210	771 754-789	
Age-std	16,268 16,167-16,369	239 230-249	190 182-199	748 731-765	

Table continued on next page

Table e7 continued

Age (yrs)	Pulmonary embolism		VTE (excluding PE)		Abdominal aortic aneurysm		Peripheral arterial disease	
Females	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI	Rate*	95% CI
1-9	--	-	--	-	--	-	--	-
10-19	46	32-67	81	61-108	--	-	37	24-55
20-29	273	230-324	366	316-424	--	-	45	30-69
30-39	294	254-341	449	399-506	--	-	82	62-108
40-49	437	394-484	637	585-694	25	16-39	223	193-258
50-54	587	516-668	813	728-907	53	35-81	517	451-593
55-59	730	646-826	901	806-1007	72	48-106	657	577-748
60-64	1079	975-1194	1281	1167-1407	145	111-191	1140	1033-1257
65-69	1818	1676-1973	1946	1798-2107	298	244-365	1655	1519-1803
70-74	2298	2116-2494	2488	2298-2694	792	689-910	2356	2171-2555
75-79	3305	3069-3558	3371	3132-3629	1288	1146-1449	3824	3569-4098
80-84	3853	3569-4159	4086	3791-4404	1893	1699-2109	4868	4544-5215
85+	4361	4066-4677	5242	4914-5592	2270	2061-2499	6503	6134-6893
No. cases	4853		5629		1447		4964	
Person yrs	5,136,702		5,103,956		5,169,422		5,129,243	
Crude	945	919-972	1103	1074-1132	280	266-295	968	941-995
Age-std	845	821-869	996	970-1022	235	223-247	846	823-870
Males								
1-9	--	-	--	-	--	-	--	-
10-19	--	-	35	23-53	--	-	20	12-34
20-29	116	91-148	250	212-295	21	12-38	39	26-60
30-39	223	189-264	451	401-507	--	-	98	76-126
40-49	408	367-453	696	642-755	46	34-64	337	300-379
50-54	742	662-831	999	905-1102	107	79-144	1065	969-1171
55-59	929	834-1036	1360	1243-1488	272	223-332	1838	1701-1986
60-64	1458	1335-1592	1794	1657-1942	1371	1252-1500	2697	2527-2878
65-69	1913	1764-2075	2307	2141-2485	3001	2813-3202	3789	3574-4017
70-74	2606	2403-2826	2705	2497-2930	3052	2832-3289	5280	4983-5595
75-79	3385	3126-3666	3352	3093-3634	4485	4184-4808	6557	6183-6953
80-84	3900	3567-4264	4085	3741-4460	6164	5738-6621	8242	7737-8779
85+	4401	3993-4850	4467	4053-4924	7695	7146-8287	9335	8714-10,000
No. cases	4334		5293		4524		7518	
Person yrs	5,091,009		5,068,245		5,095,970		5,049,641	
Crude	851	826-877	1044	1017-1073	888	862-914	1489	1456-1523
Age-std	881	855-907	1069	1040-1098	964	936-992	1598	1562-1635

Table continued on next page

Table e7 continued

Both				
1-9	-- -	-- -	-- -	-- -
10-19	29 21-41	57 46-72	-- -	28 20-39
20-29	189 164-217	304 272-339	13 8-23	42 31-56
30-39	259 232-289	450 414-489	15 9-23	90 75-108
40-49	422 392-455	667 629-707	36 28-46	280 256-307
50-54	665 611-725	907 843-976	80 63-102	793 734-857
55-59	830 765-901	1132 1056-1214	172 144-206	1249 1168-1334
60-64	1267 1186-1354	1536 1445-1631	752 690-819	1907 1806-2013
65-69	1865 1760-1975	2123 2011-2241	1613 1516-1715	2687 2561-2820
70-74	2444 2307-2589	2591 2449-2742	1858 1739-1985	3724 3552-3904
75-79	3342 3165-3528	3363 3185-3551	2727 2569-2895	5047 4826-5277
80-84	3873 3654-4104	4086 3859-4325	3656 3444-3881	6257 5973-6555
85+	4375 4133-4630	4978 4717-5254	4072 3840-4318	7446 7122-7785
No. cases	9187	10,922	5971	12,482
Person yrs	10,227,711	10,172,201	10,265,391	10,178,884
Crude	898 880-917	1074 1054-1094	582 567-597	1226 1205-1248
Age-std	861 844-879	1035 1015-1054	555 541-570	1190 1169-1211

*Rates are given per 1,000,000 person years. Cases and person years are numbers; all other figures are rates.

Abbreviations – yrs: years; CI: confidence interval; No.cases: total number of cases; Person yrs: Total person-years; Age-std: age-standardized

References

- [1] Jones DA, Candio P, Shakir R, Ntentas G, Ramroth J, Gray AM, et al. Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry. *Blood Adv* 2022;6:909–19. doi:10.1182/bloodadvances.2021006254.
- [2] Cutter DJ, Ramroth J, Diez P, Buckle A, Ntentas G, Popova B, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma. *J Clin Oncol* 2021;39:3591–601. doi:10.1200/JCO.21.00408.
- [3] WHO mortality statistics n.d.
http://apps.who.int/healthinfo/statistics/mortality/causeofdeath_query/ (accessed November 15, 2017).